A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, and Safety of Mavrilimumab in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2015
Price : $35 *
At a glance
- Drugs Mavrilimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors MedImmune
- 08 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2014 Planned number of patients changed from 60 to 24 as reported by ClinicalTrials.gov record.
- 08 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.